VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development ...
Another wave of layoffs has hit one of the Bay Area's biggest biotech companies—and the latest cuts push a troubling trend ...
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing ...
New York invests $65M in biotech with new clinical trial consortium and Biogenesis Park to compete with Boston, San Francisco ...
Global CRO highlights multi-regional trial delivery, early-phase Australia advantages, and expanding support for biotech sponsors across Asia and China ...
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for ...
Based on its sound industrial ecosystem and strong policy support, Zhangjiang Pharma Valley in Shanghai is witnessing ...
BioProcess International reviews key biotech trends from the first half of 2026, including US onshoring, China's biologics ...
In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...
As U.S. lawmakers continue to scrutinize the consequences of China’s expanding role in biotech innovation, industry insiders ...
Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong ...
Customs Department has initiated probe against its general manager, sales and marketing officer Sreekant Sreedharan of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results